Search clinical trials for: mFOLFOXIRI

Total 17 results

Pei-Rong Ding
Fujian Cancer Hospital; Shantou Central Hospital; Liaoning Tumor Hospital & Institute and other collaborators

Recruiting

Short-course Radiotherapy or Long-course Chemoradiation Followed by mFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Rectal Neoplasms

China
Sun Yat-sen University
Guangzhou Burning Rock Dx Co., Ltd.

Recruiting

MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer (MIRROR)

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (CEIL)

Metastatic Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer (OPTICAL-2)

Colorectal Cancer

China
Yanhong Deng

Not yet recruiting

Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) (AFFORD)

Colorectal Cancer
First Affiliated Hospital of Wenzhou Medical University

Recruiting

mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer

Colorectal Cancer

China
Dominik Paul Modest
German Research Foundation; Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Colorectal Cancer

Germany
Fudan University

Recruiting

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Liver Metastases | Colorectal Carcinoma

China
Fudan University

Recruiting

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases

China
First Affiliated Hospital of Zhejiang University
Zhejiang Cancer Hospital; First Affiliated Hospital of Wenzhou Medical University

Recruiting

A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC

Locally Advanced Rectal Cancer

China
Sun Yat-sen University

Recruiting

mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer (FANTASTIC)

Colorectal Cancer

China
Yanhong Deng

Recruiting

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer (TRIBE-C)

Colorectal Cancer

China
Yanhong Deng

Recruiting

Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (FOBEAR)

Rectal Cancer

China
Khon Kaen University

Recruiting

Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma

Cholangiocarcinoma

Thailand
Gruppo Oncologico del Nord-Ovest

Active, not recruiting

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC)

Metastatic Colorectal Cancer

Italy
Gruppo Oncologico del Nord-Ovest

Completed

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (TRIPLETE)

Metastatic Colorectal Cancer

Italy
First Affiliated Hospital of Zhejiang University

Unknown

Neoadjuvant mFOLFOXIRI Chemotherapy Alone for Extramural Vascular Invasion Positive Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China

3

Subscribe